<DOC>
	<DOCNO>NCT02891226</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness study drug LY3074828 participant active Crohn 's Disease .</brief_summary>
	<brief_title>A Study LY3074828 Participants With Active Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Active Crohn 's Disease ( CD ) determine SESCD , participant report stool frequency abdominal pain . Inadequate response failure tolerate least one following : aminosalicylates ; budesonide ; systemic corticosteroid ; immunosuppressant ( eg , azathioprine , 6mercaptopurine , methotrexate ) ; prior exposure biologics treatment CD . Have complication CD stricture , stenosis , manifestation surgery might indicate , could confound evaluation efficacy . Diagnosis condition affect digestive tract , ulcerative colitis , indeterminate colitis , fistulizing disease , abdominal perianal abscess , adenomatous colonic polyp excise , colonic mucosal dysplasia , short bowel syndrome . Have kind bowel resection , diversion , placement stoma within 6 month intraabdominal surgery within 3 month prior screen . Are unsuitable inclusion study opinion investigator sponsor reason may compromise subject 's safety confound data interpretation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>inflammatory bowel disease</keyword>
	<keyword>IL-23</keyword>
	<keyword>biologic</keyword>
</DOC>